Compare KKR & Co Inc (KKR) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KKR & Co Inc vs McKesson Corporation — how do they compare? KKR & Co Inc trades at $90.95 (market cap $80.39B), while McKesson Corporation trades at $938.84 (market cap $108.46B). The key difference: McKesson Corporation is the larger of the two by market cap, and KKR & Co Inc pays the higher dividend (0.87%). Which is the better fit depends on your goals — on Pluang, investors hold KKR & Co Inc for 67 Days and McKesson Corporation for 74 Days on average.
| KKR | MCK | |
|---|---|---|
Market Cap | $80.39B | $108.46B |
Volume | 6,517,705 | 712,607 |
Sector | Financials | Health |
52-Week High | $142.75 | $995.69 |
52-Week Low | $83.88 | $725.17 |
Typical Hold Time | 67 Days | 74 Days |
Enterprise Value | $2.95B | $115.00B |
Dividend Yield | 0.87% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KKR trades at $89.56, down 0.12% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. Recent earnings show a mixed track record, with Q2 2026 beating estimates but Q4 2025 missing. The company maintains strong analyst support with a consensus price target of $123.30 and 24 buy ratings. Recent news highlights active deal-making, including a joint venture with Thomson Reuters and investments in AI infrastructure, signaling ongoing strategic expansion.
The outlook for KKR is positive based on robust analyst sentiment and strategic investments, but risks include volatile cash flows and high debt levels. Investors may find opportunity in the significant upside to the price target, though macroeconomic sensitivity and execution risks warrant caution.
McKesson (MCK) trades at $930.25, up 2.19% today, with a bullish technical outlook and strong analyst support. The stock shows consistent earnings beats, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue growth is robust, reaching $359.05B in 2025, though net margins are thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing long-term visibility.
The outlook is positive, driven by operational strength and strategic partnerships, but investors face risks from margin pressure and drug pricing uncertainty. With 81% of analysts rating it Buy and a consensus target of $956.43, the stock offers upside, though high RSI levels suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
